Welcome to the REMS Program Administered by Celgene

To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the REMS products THALOMID® (thalidomide), REVLIMID® (lenalidomide), lenalidomide and POMALYST® (pomalidomide). The THALOMID REMS® program, Lenalidomide REMS program and POMALYST REMS® program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.

If you would like to obtain more information about any of the Celgene-administered REMS programs, please click on the program name below:

www.LenalidomideREMS.com, to learn more about the Lenalidomide REMS program.
www.POMALYSTREMS.com, to learn more about the POMALYST REMS® program.
www.THALOMIDREMS.com, to learn more about the THALOMID REMS® program.

For prescribers, please enter your User Name and Password to manage your patients through a Celgene-administered REMS program. If you do not have an online account, select Create User Account to establish an account. Patients currently enrolled in a Celgene-administered REMS program are not required to create an online account to complete a survey. Please select Patient Surveys and enter the information requested to begin a survey.

To login to your account:
User Name
Forgot Password?